Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of GC4419 in Healthy Subjects
NCT03163173Phase 1Completed
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avasopasem manganese in oral mucositis (OM), sponsored by Galera Therapeutics, Inc. Primary endpoints: Mass balance of GC4419, Total radioactivity in plasma (AUC0-t) and 4 more. Started Aug 2017; status: completed.
02
Drugs
avasopasem manganese
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT03163173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163173.